Can You Start Mounjaro at 5mg? What the Dosing Schedule Actually Says

Why can't you begin Mounjaro at 5mg?

The short answer is that the medicine's licence (and the clinical evidence behind it) are built around a 2.5mg starting point. Tirzepatide is a dual GIP and GLP-1 receptor agonist, which means it works on two gut-hormone pathways at once. That dual action is part of what makes it effective, but it also means the body needs time to adapt. Gastrointestinal side effects (nausea in particular) are most pronounced when a new GLP-1 or dual-agonist treatment starts or when the dose rises. Beginning at a lower exposure and building gradually is the approach that made these medicines tolerable enough to use in practice.

The NHS tirzepatide medicines page confirms that treatment opens at 2.5mg once weekly. The summary of product characteristics (SmPC) reflects the same schedule. No part of the licensed guidance supports opening at 5mg, and a prescriber who skipped straight there would be departing from that evidence base without a clinical justification to do so.

It is worth being clear about what 2.5mg is and what it is not. It is a tolerability dose, its job is to settle your system into the medicine, not to deliver the full therapeutic effect. Expecting significant weight loss in those first four weeks, while your body adjusts, sets the bar in the wrong place. Most people find those weeks manageable precisely because the dose is gentle.

When does 5mg actually come into the schedule?

After your first four weeks at 2.5mg, your prescriber reviews how you have been getting on. If tolerance has been reasonable and there are no clinical reasons to pause, the standard next step is 5mg for the following four-week period. From there, the titration continues in roughly four-weekly increments: 7.5mg, 10mg, 12.5mg and finally 15mg, though not everyone reaches the top, and not everyone needs to. The target is the dose at which you are losing weight well and tolerating treatment comfortably, which varies between people.

If you have had a difficult time at 2.5mg (persistent nausea, vomiting, or significant digestive upset) your prescriber may recommend staying at 2.5mg for a second four-week block before stepping up. There is no rule that the move to 5mg must happen at exactly week five. Equally, if side effects were minimal and your clinical picture supports it, the step up can proceed as planned. The key point is that a prescriber makes that call, not a countdown timer. Anyone asking whether they can start at 5mg for weight-loss purposes is often really asking whether they can get to the effective doses faster, a question worth raising directly with your clinical team.

If you are curious about the logic behind the 2.5mg entry point specifically, the question of whether 2.5mg is truly mandatory is explored in more detail elsewhere. The brief answer: yes, in routine practice, it is.

What about people transferring from another clinic, can they skip to 5mg?

This is one of the questions our prescribers hear regularly. If someone is already established on Mounjaro at 5mg or higher through another provider and wants to continue treatment, the starting point for a transfer is not the same as the starting point for a brand-new patient. In that situation, the prescriber reviews evidence of the current dose (such as recent dispensing records or a letter from the previous clinic) and, if everything checks out, can continue at the current dose rather than dropping back to 2.5mg.

That is a transfer scenario, though, not a fresh start. A new patient beginning Mounjaro for the first time starts at 2.5mg. A patient re-starting after a long break may also be asked to go back to the beginning, because the tolerability rationale applies all over again once the body has lost its adaptation to the medicine. The 5mg Mounjaro pen page covers more on what this dose period looks like in practice, including what a typical four-week experience involves. For anyone thinking about the step that follows (moving from 5mg to 7.5mg) this page on starting at 7.5mg explains when that transition typically happens and what your prescriber looks for before approving it.

Does the starting dose affect your overall results?

A reasonable concern, and the evidence is reassuring on this. The SURMOUNT-1 trial (published in the New England Journal of Medicine and forming a core part of NICE's appraisal of tirzepatide (TA1026)) showed average body-weight reductions of around 20 to 21% at the 15mg dose over 72 weeks. All participants in that trial followed the same stepped schedule, beginning at 2.5mg. The gradual build-up did not blunt those results; it was part of the protocol that produced them.

Trying to accelerate through the early doses in the hope of reaching a higher therapeutic level sooner is not supported by evidence and carries a real risk of making side effects worse, which can in turn make it harder to stay on treatment at all. A few weeks of lower-dose adjustment is a small trade for months of better tolerability ahead. If you are thinking about cost as part of this picture, the Mounjaro pricing page sets out what private treatment typically costs across the dose journey in the UK, which is a useful thing to know before you begin. Mounjaro is available in six strengths for a reason, the full range from 2.5mg to 15mg is covered in the overview of starting doses if you want the broader picture before booking a consultation.

Starting Mounjaro at the right dose, with a prescriber who has read your full medical picture, is the step that everything else depends on. Check your eligibility and speak to one of our clinical team by starting a free consultation.